Increased Microerythrocyte Count in Homozygous α+-Thalassaemia Contributes to Protection against Severe Malarial Anaemia

doi:10.1371/journal.pmed.0050056

PLoS Med. 2008 March; 5(3): e56.

Published online 2008 March 18. doi: 10.1371/journal.pmed.0050056

PMCID: PMC2267813

Copyright : © 2008 Fowkes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Increased Microerythrocyte Count in Homozygous α⁺-Thalassaemia Contributes to Protection against Severe Malarial Anaemia

Freya J. I Fowkes,^1,² Stephen J Allen,³^¤a Angela Allen,³ Michael P Alpers,⁴^¤b David J Weatherall,³ and Karen P Day²^*

¹ Peter Medawar Building for Pathogen Research and Department of Zoology, University of Oxford, Oxford, United Kingdom

² Department of Medical Parasitology, New York University School of Medicine, New York, New York, United States of America

³ The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

⁴ PNG Institute of Medical Research, Goroka, Papua New Guinea

Geoffrey Pasvol, Academic Editor

Imperial College London, United Kingdom

* To whom correspondence should be addressed. E-mail: karen.day/at/med.nyu.edu

Received April 10, 2007; Accepted January 21, 2008.

This article has been cited by other articles in PMC.

Abstract

Background

The heritable haemoglobinopathy α⁺-thalassaemia is caused by the reduced synthesis of α-globin chains that form part of normal adult haemoglobin (Hb). Individuals homozygous for α⁺-thalassaemia have microcytosis and an increased erythrocyte count. α⁺-Thalassaemia homozygosity confers considerable protection against severe malaria, including severe malarial anaemia (SMA) (Hb concentration < 50 g/l), but does not influence parasite count. We tested the hypothesis that the erythrocyte indices associated with α⁺-thalassaemia homozygosity provide a haematological benefit during acute malaria.

Methods and Findings

Data from children living on the north coast of Papua New Guinea who had participated in a case-control study of the protection afforded by α⁺-thalassaemia against severe malaria were reanalysed to assess the genotype-specific reduction in erythrocyte count and Hb levels associated with acute malarial disease. We observed a reduction in median erythrocyte count of ~1.5 × 10¹²/l in all children with acute falciparum malaria relative to values in community children (p < 0.001). We developed a simple mathematical model of the linear relationship between Hb concentration and erythrocyte count. This model predicted that children homozygous for α⁺-thalassaemia lose less Hb than children of normal genotype for a reduction in erythrocyte count of >1.1 × 10¹²/l as a result of the reduced mean cell Hb in homozygous α⁺-thalassaemia. In addition, children homozygous for α⁺-thalassaemia require a 10% greater reduction in erythrocyte count than children of normal genotype (p = 0.02) for Hb concentration to fall to 50 g/l, the cutoff for SMA. We estimated that the haematological profile in children homozygous for α⁺-thalassaemia reduces the risk of SMA during acute malaria compared to children of normal genotype (relative risk 0.52; 95% confidence interval [CI] 0.24–1.12, p = 0.09).

Conclusions

The increased erythrocyte count and microcytosis in children homozygous for α⁺-thalassaemia may contribute substantially to their protection against SMA. A lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous strategy against the significant reduction in erythrocyte count that occurs during acute infection with the malaria parasite Plasmodium falciparum. This haematological profile may reduce the risk of anaemia by other Plasmodium species, as well as other causes of anaemia. Other host polymorphisms that induce an increased erythrocyte count and microcytosis may confer a similar advantage.

Editors' Summary

Background.

Mutations (changes in the DNA that encodes proteins) continually arise within human populations. Harmful mutations that affect an individual's ability to reproduce usually disappear, but most other mutations persist at a low frequency. Some mutations, however, protect their human carriers against specific disease-causing organisms, and consequently occur at high frequencies in human populations that live in places where these organisms are common. For example, the inherited blood disorder α⁺-thalassemia, which is common in Africa and Southeast Asia, provides protection against malaria, a parasitic disease that occurs in tropical and subtropical parts of the world. α⁺-Thalassemia is caused by the loss of one or more of the genes that encode the α chains of hemoglobin, the red blood cell (erythrocyte) protein that carries oxygen around the body. These α chains are normally encoded by four genes, two on each Chromosome 16 (all chromosomes come in pairs). People with heterozygous α⁺-thalassemia lack one copy of the α chain gene and have a –α/αα genotype (genetic makeup). People with homozygous α⁺-thalassemia lack one copy of the gene on each chromosome (they have a –α/–α genotype) and have mild “microcytic anemia,” a condition characterized by increased numbers of abnormally small erythrocytes (microcytosis) that contain reduced amounts of hemoglobin.

Why Was This Study Done?

Paradoxically, although homozygous α⁺-thalassemia causes mild anemia, it provides protection against severe malarial anemia, a potentially fatal complication of malaria. Malaria parasites cause anemia because they multiply inside erythrocytes and rupture them. Scientists originally thought that α⁺-thalassemia protects against malaria by interfering with the parasite's ability to infect erythrocytes, but the evidence collected so far does not support this hypothesis. In this study, therefore, the researchers have investigated whether the microcytosis and increased erythrocyte count associated with α⁺-thalassemia might be responsible for the protection that this blood disorder provides against severe malarial anemia. Specifically, they asked whether this hematological (blood) profile protects against severe malarial anemia because people with the –α/–α genotype lose less hemoglobin for a given degree of malaria-induced erythrocyte loss than do those with the normal genotype.

What Did the Researchers Do and Find?

A study done in the mid 1990s in children living on the north coast of Papua New Guinea (where 68% of the population has α⁺-thalassemia) showed that homozygous α⁺-thalassemia protects against severe malaria. To investigate why, the researchers re-analyzed the genotype-specific reduction in erythrocyte counts and hemoglobin levels associated with acute malarial disease in these children and developed a simple mathematical model to predict hemoglobin levels after malaria infection. They found that when malarial infection reduced the number of erythrocytes per liter of blood by more than 1.1 × 10¹² (the average measured loss of erythrocytes in this population because of malaria was 1.5 × 10¹² per liter), children with homozygous α⁺-thalassemia lost less hemoglobin than did those with the normal genotype. Furthermore, children with homozygous α⁺-thalassemia needed a 10% greater reduction in their red blood cell count than children with the normal genotype for their hemoglobin levels to fall below the value that defines severe malarial anemia.

What Do These Findings Mean?

These findings suggest that the increased number of abnormally small erythrocytes associated with homozygous α⁺-thalassemia might be responsible for the protection against severe malarial anemia that this blood disorder provides, because more erythrocytes have to be destroyed by the parasite to reduce hemoglobin concentrations to a dangerous level than in people with the normal genotype. In other words, a lower concentration of hemoglobin per erythrocyte coupled with a larger population of erythrocytes might be advantageous in the face of the large reduction in erythrocyte numbers caused by infection with malaria parasites. The researchers note that their study population was infected with only one type of malaria parasite (Plasmodium falciparum), but speculate that the hematological profile associated with α⁺-thalassemia might also prevent other Plasmodium species causing anemia. Futhermore, they suggest, other mutations that increase the erythrocyte count and cause microcytosis might protect against severe malaria anemia in a similar fashion.

Additional Information.

Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050056.

The MedlinePlus encyclopedia contains pages on thalassemia and on malaria (in English and Spanish)
Detailed information is available on thalassemia (including useful links to other resources) from the US National Heart Lung and Blood Institute, from the US National Human Genome Research Institute, from the Cooley's Anemia Foundation, and from MedlinePlus
The US Centers for Disease Control and Prevention provide information on malaria (in English and Spanish)
Information is also available from the World Health Organization on malaria (in English, Spanish, French, Russian, Arabic, and Chinese)

Introduction

The heritable haemoglobinopathy α-thalassaemia is one of the most common monogenic disorders of humans [1]. The different forms of α⁺-thalassaemia result from deletions (3.7 or 4.2 kb) or point mutations in one of the duplicated α-globin genes (αα/αα) on Chromosome 16 [1]. The heterozygous (−α/αα) and homozygous (−α/−α) states for α⁺-thalassaemia are characterised by lower haemoglobin (Hb) concentration, mean cell volume (MCV) and mean cell Hb (MCH), but increased erythrocyte count compared with normal individuals [1–3]. This mild hypochromic, microcytic anaemia is more pronounced in individuals homozygous for α⁺-thalassaemia compared to heterozygous individuals [1–3].

Haldane's proposal that the high frequencies of thalassaemias in malaria endemic regions were due to natural selection by malaria [4] is consistent with the strong geographical correlation between the frequency of α⁺-thalassaemia and malaria in the Pacific region [5]. It has been suggested that α⁺-thalassaemia protects by a direct interaction between the parasite (Plasmodium falciparum) and the altered thalassaemic erythrocyte, resulting in reduced parasite load [6]. However, in vitro experiments have failed to consistently demonstrate either a reduced ability of the malaria parasite to grow in and/or invade thalassaemic erythrocytes [7–17], and epidemiological studies have failed to demonstrate any consistent effect of α⁺-thalassaemia against P. falciparum density [18–22]. These findings argue against an altered physical interaction between the erythrocyte and the parasite.

Case-control studies in Papua New Guinea (PNG) [18] and Africa [19,20,22,23] have demonstrated the protective effect of α⁺-thalassaemia against severe malaria. Most studies show that α⁺-thalassaemia homozygotes have considerable protection against SMA compared to heterozygotes [18,20,22,23], although one study showed equal odds of heterozygotes and homozygotes developing SMA [19]. We hypothesised that this striking protection against SMA may be due to the microcytosis and increased erythrocyte count in children homozygous for α⁺-thalassaemia.

We have reported previously a case-control study of children living in the north coastal region of PNG that showed that the odds ratio for SMA was 0.34 (95% confidence interval [CI] 0.16–0.73) in homozygous α⁺-thalassaemia compared to normal individuals [15]. In the present study, we explore the consequences of a range of reductions of erythrocyte count on genotype-specific Hb levels by modelling the observed haematological data from the original case-control study.

Materials and Methods

Study Site

The north coast of PNG provides a unique site to investigate the protective effect of α⁺-thalassaemia against malaria. The frequency of α⁺-thalassaemia is very high (68%) [1], and other host erythrocyte polymorphisms such as Southeast Asian ovalocytosis and glucose-6-phosphate dehydrogenase deficiency are relatively uncommon in this population (<7%) [18,21]. Importantly, sickle cell trait, a haemoglobinopathy proposed to be a serious confounder in epidemiological studies of α⁺-thalassaemia in Africa [24,25], is absent in PNG.

Data Collection

In the case-control study, children with acute malaria were recruited from outpatient clinics and Madang General Hospital between October 1993 and February 1996 [18]. In children admitted to hospital, malaria was defined as a febrile illness with any degree of P. falciparum parasitaemia (as they had often received antimalarial treatment before admission), but without an alternative cause of illness identified during detailed clinical and laboratory investigation. Some of these children developed one or more severe manifestations of malaria, defined according to World Health Organization criteria [26,27]. For each case of severe malaria, a control child living in the community was selected randomly and individually matched to the index case for age, sex, ethnicity, season, and village. Children in the community frequently harbour chronic, asymptomatic P. falciparum, P. vivax, P. malariae, and P. ovale [28]. Analysis of the protective effect of α⁺-thalassaemia against severe manifestations of malaria accounted for the matched pair design. Children attending clinics with P. falciparum parasitaemia ≥10,000/μl and no clinical or laboratory features of severe malaria or an alternative cause of an acute febrile illness were also recruited. To investigate the effect of the haematological characteristics according to α⁺-globin genotype on anaemia associated with malaria infection of varying severity, we have pooled children from our original clinic and hospital malaria groups together.

Venous blood was collected from all children at presentation. Thick and thin blood films were prepared, stained with Giemsa, and examined by microscopy for the presence of malaria parasites. Blood collected into EDTA was used for measurement of Hb, erythrocyte count, MCV, and MCH (Coulter MD8 instrument, Coulter Electronics). These measurements were done promptly after sample collection, and reliability of results was ensured by participation in the Coulter instruments quality control scheme. P. falciparum density per microlitre of whole blood was calculated accurately by using the individual measured leukocyte count and parasites per 200 leukocytes counted in thick films. These calculations of parasitaemia differ from standard malariological methods that use only a population average leukocyte count to calculate parasites per microlitre of blood. Percentage parasitaemia was calculated by dividing an individual child's P. falciparum count per microlitre by the number of erythrocytes per microlitre of whole blood measured for that child.

Informed consent was obtained from all individuals and/or their parents or guardian. The study was approved by the Medical Research Advisory Committee of PNG, the Central Oxford Research Ethics Committee, and the Oxford Tropical Research Ethics Committee.

Data Analysis

Analysis of all haematological data revealed a linear relationship between Hb and erythrocyte count (Figure S1). Children with acute malaria, regardless of conventional severity definitions, demonstrated a reduction in erythrocyte counts and Hb concentrations compared to community control children (Figure S1). Given that Hb concentration was used as a definition for severe disease, and the continuous nature of Hb data, we decided to pool acute malaria data for the purpose of analysis. The association of malaria severity and α⁺-thalassaemia genotype with categorical variables were assessed using chi-squared tests or Fisher's exact test, and continuous data by Mann Whitney U or Kruskal-Wallis tests. The association of α⁺-thalassaemia genotype with risk of SMA was assessed using logistic regression. SPSS (for Windows Release 13.0. 2004, SPSS) was used for data analysis.

Mathematical Model

Children who are homozygous for α⁺-thalassaemia have smaller erythrocytes containing less Hb and a greater erythrocyte count than children of normal genotype both when living in the community and during episodes of acute malaria. We proposed that this haematological profile protects against SMA because homozygous children lose less Hb from their total erythrocyte pool of Hb, for a given degree of erythrocyte loss, compared with those of normal genotype. A simple model was developed, using data from community children, which predicts total Hb concentration after acute malaria infection as a function of three parameters; (1) baseline level of Hb, (2) MCH, and (3) the reduction in erythrocyte count during a malaria infection. The linear equation y_i = b − m_ix was used to predict Hb concentrations where y_i refers to predicted Hb concentration in the ith child, b is the observed genotype-specific median Hb concentration observed in community children prior to acute malarial infection, m_i represents the observed genotype-specific MCH in the ith child, and x represents a fixed number of erythrocyte loss during a malaria infection. Values for b and m_i were taken from values observed in the community children, among which all α⁺-thalassaemia genotypes were represented. A range of values for x were imputed into the equation in order to derive a slope line for total Hb by reduction in erythrocyte count; separate slope lines were developed for each α⁺-thalassaemia genotype.

Results

Characteristics of Study Population

We reanalysed the data from 547 children with acute malaria (median [interquartile range] age 3.0 years [1.8–4.7]; 53.7% male) and 280 children living in the community (3.1 years [1.7–4.5], p = 0.81; 53.3% male, p = 0.88) who had participated in the earlier study [15].

Haematological Indices by Disease Status and α⁺-Thalassaemia Genotype

The frequency of α⁺-thalassaemia was high (>80%) in this population (Table 1). Total erythrocyte count was found in the order of normal < heterozygote < homozygote within each clinical group (p ≤ 0.001) (Table 1). Values for MCH and MCV were found in the opposite order, i.e., normal > heterozygote > homozygote (p < 0.001) (Table 1). As noted in previous studies in Melanesia [2,3], erythrocyte counts, MCH, and MCV were age-dependent (unpublished data). Age was distributed equally among α⁺-thalassaemia genotypes in community children (p = 0.17) and those with acute malaria (p = 0.98), so it was not a confounder in the analysis presented here. Furthermore, adjustments for age made no difference in the association between α⁺-thalassaemia genotype and haematological indices.

Table 1

Haematological Indices in Community Children and Children with Acute Malaria According to α⁺-Thalassaemia Genotype

Although Hb concentration was found in the order of normal > heterozygote > homozygote in children living in the community, the increased erythrocyte count in children with α⁺-thalassaemia appeared to compensate somewhat for the microcytosis as there was no significant difference in Hb concentrations according to genotype (p = 0.15) (Table 1). Interestingly, the order in Hb concentration was reversed in children with acute malaria, i.e., normal < heterozygote < homozygote (Table 1). The difference in median Hb concentration between community controls and acute malaria groups was lower in children homozygous for α⁺-thalassaemia than in children of normal genotype (Table 1).

This difference in Hb loss according to genotype could not be accounted for by differences in parasitaemia. Children with acute malaria had significantly higher P. falciparum densities (18,880 parasites/μl [3,142–73,950]) than children living in the community (n = 104, 1,974 parasites/μl [308–9,233], p < 0.001). Parasite counts per microlitre of blood and percent parasitaemia (which adjusts for genotype-specific differences in erythrocyte count) were similar among α⁺-thalassaemia genotypes in both children living in the community and those with acute malaria (Figure 1, p ≥ 0.3). The median erythrocyte count was 1.5 × 10¹²/l lower in children with acute malaria (3.27 × 10¹²/l [2.11–4.44]) than community children (4.78 × 10¹²/l [4.24–5.24], p < 0.001) and, in contrast to Hb concentration, this difference in erythrocyte count was remarkably similar across all genotypes (Table 1).

Figure 1

Parasite Density in Community Children and Those with Acute Malaria According to α⁺-Thalassaemia Genotype

Decrease in Hb According to Genotype-specific Differences in MCH

MCH was 20% lower in community children homozygous for α⁺-thalassaemia than in individuals of normal genotype (p < 0.001, Table 1). Thus, for a given degree of reduction in erythrocyte count, children who are homozygous for α⁺-thalassaemia will release 20% less Hb from the erythrocyte pool of Hb than those of normal genotype. Using the MCH values for each child living in the community and on the basis of the linear relationship between Hb and erythrocyte count represented by the linear equation y_i = b − m_ix, we calculated the reduction in Hb concentration for the range of differences in erythrocyte count observed between community controls and acute malaria (Figure 2A and and2B).2B). This simple model predicted that at degrees of reduction in erythrocyte count <1.1 × 10¹²/l, α⁺-thalassaemia homozygotes had a lower Hb concentration compared to normal individuals. In contrast, at levels of reduction in erythrocyte count >1.1 × 10¹²/l, children homozygous for α⁺-thalassaemia had a higher Hb concentration than those of normal genotype (Figure 2B and and22C).

Figure 2

Consequence of Reduction in Erythrocyte Count on Total Haemoglobin Concentration According to α⁺-Thalassaemia Genotype

Erythrocyte Count Cutoff for SMA According to Genotype

Children homozygous for α⁺-thalassaemia with lower MCH and increased erythrocyte count may require a greater reduction in erythrocyte count to develop SMA, defined as Hb concentration <50 g/l [26]. To determine the genotype-specific erythrocyte count cutoff for a Hb concentration of 50 g/l, erythrocyte count was plotted against Hb concentration for all children with acute malaria and a line of best fit drawn for each genotype (Figure 3). The erythrocyte count cutoff for SMA was determined to be 2.4 × 10¹²/l in homozygous α⁺-thalassaemia, 2.2 × 10¹²/l in heterozygotes, and 2.0 × 10¹²/l in normal individuals (Figure 3), because of differences in MCH values among genotypes.

Figure 3

Genotype-Specific Erythrocyte Cutoffs for Severe Malarial Anaemia

For each child living in the community, the reduction in erythrocyte count required to reach an Hb concentration of 50 g/l was calculated. The median (interquartile range) erythrocyte loss was higher in homozygous α⁺-thalassaemia (2.58 × 10¹²/l [2.14–3.02]), than heterozygous α⁺-thalassaemia (2.46 × 10¹²/l [1.86–2.8], p = 0.08), and normal individuals (2.35 × 10¹²/l [1.63–2.82], p = 0.02). In other words, children homozygous for α⁺-thalassaemia would require 10% greater reduction in erythrocyte count than children of normal genotype, for Hb concentration to fall to 50 g/l. This result should be considered in relation to our observation that similar degrees of reduction in erythrocyte count were found among α⁺-thalassaemia genotypes in acute disease, relative to community controls (~1.5 × 10¹²/l; Table 1).

To determine whether microcytosis and increased erythrocyte count could explain the protection observed against SMA in α⁺-thalassaemia homozygotes, we applied the reduction of 2.35 × 10¹²/l erythrocytes (the median reduction in erythrocyte count observed in children of normal genotype in the estimated transition between community control and SMA) to all children living in the community. The proportion of community children predicted to develop SMA, defined by the genotype-specific erythrocyte count definitions for SMA, was lower in children who were homozygous for α⁺-thalassaemia (n = 50, 35.7%) than in heterozygous children (n = 36, 43.9%), and those of normal genotype (n = 17, 51.5%). Compared with normal children, the risk of a community child being defined as having SMA was 0.52 (95% confidence interval [CI] 0.24–1.12, p = 0.09) in α⁺-thalassaemia homozygotes and 0.74 (95% confidence interval [CI] 0.33–1.66, p = 0.46) in heterozygotes for this degree of reduction in erythrocyte count. This simple model based on observed haematological data predicted that children who were homozygous for α⁺-thalassaemia would be 48% less likely to develop SMA than children of normal genotype.

Discussion

The reasons for the microcytosis and relatively high erythrocyte count in carriers for alpha or beta thalassaemia are not understood. It has been proposed that it reflects an increased number of terminal cell divisions during erythropoiesis, due to the combination of defective haemoglobinisation of the erythrocytes and a highly proliferative bone marrow [29]. We investigated whether the microcytosis and increased erythrocyte count associated with α⁺-thalassaemia may be a haematological advantage in the face of the estimated >30% reduction in erythrocyte count, which we observed in PNG children with acute malaria.

Modelling observed data, we show that a lower concentration of Hb per erythrocyte and a larger population of erythrocytes may be a biologically advantageous host strategy against a pathogen that significantly lowers erythrocyte count. We define a crossover point of reduction in erythrocyte count due to acute malaria (1.1 × 10¹²/l) at which microcytosis and an increased erythrocyte count becomes an advantage to the host. This erythrocyte cutoff is considerably lower than the median erythrocyte reduction we estimated to be associated with acute malaria (~1.5 × 10¹²/l). This result would account for the reversal of Hb concentrations in children with acute malaria (normal < heterozygote < homozygote), a phenomenon that has been noted previously [16,29]. We show that the erythrocyte count associated with this Hb concentration cutoff is genotype-specific and found in the order normal < heterozygous < homozygous. We also show that children homozygous for α⁺-thalassaemia would require a greater reduction in erythrocyte count to reach the SMA cutoff. We therefore propose that a higher microcytic erythrocyte count in children homozygous for α⁺-thalassaemia enables them to maintain their Hb concentration above the 50 g/l threshold, thereby reducing the risk of SMA. Indeed, given the degree of malaria haemolysis associated with SMA in normal individuals, children who were homozygous for α⁺-thalassaemia would be 48% less likely to develop SMA than children of normal genotype. This result suggests that microcytosis and increased erythrocyte count contribute considerably to the 66% protection against SMA observed in individuals homozygous for α⁺-thalassaemia in this population [18].

We found no significant difference in parasite counts per microlitre of blood or percent parasitaemia among α⁺-thalassaemia genotypes in community children, nor in those with acute malaria, in concordance with earlier studies [15–19]. This finding is surprising given that the increased erythrocyte count in homozygous children may be expected to lower the proportion of infected erythrocytes. After adjustments for individual erythrocyte counts, the variance of parasitology data was more comparable among α⁺-thalassaemia genotypes compared to parasites per microlitre of blood. It is possible that density-dependent mechanisms [28] may regulate parasitaemia and reduce genotype-specific differences.

Malarial anaemia is attributed to parasite-induced haemolysis, destruction of unparasitised erythrocytes, and dyserythropoiesis [30]. It has been proposed that individuals with α⁺-thalassaemia have increased phagocytosis of erythrocytes [31–33] and expanded erythroid marrow [34], but the balance between erythrocyte survival and production among α⁺-thalassaemia genotypes is unknown. The model shown in Figure 2 predicts the total Hb concentration for a given reduction in erythrocyte count and fixed MCH. It does not take into account potential differences in the balance between destruction of erythrocytes and production of reticulocytes among α⁺-thalassaemia genotypes, and this area merits further research.

Other mechanisms may also contribute to the protection against SMA. α⁺-Thalassaemia homozygosity has also been shown to be associated with low complement receptor 1 (CR1) expression [35]. This molecule has been shown to be important in the binding of infected erythrocytes to noninfected erythrocytes (rosetting) [36], as well as the clearance of erythrocytes as they age [37]. Increased rosetting has been implicated in the pathogenesis of severe disease [38]. While α⁺-thalassaemic erythrocytes are less likely to form rosettes in vitro [39,40], further studies are required to investigate the contribution of complement receptor 1 (CR1) to the protection α⁺-thalassaemia affords against SMA. Both polymorphisms could synergise to minimise the reduction in erythrocyte count during acute disease.

Malaria is a complex multisystem disorder, and in children, in addition to anaemia, important severe manifestations include cerebral malaria, acidosis, and hyperlactataemia [41]. No protection of α⁺-thalassaemia was observed against malaria coma in the matched-pair analysis in the PNG study [18], whereas studies in Africa have shown a protective effect against cerebral malaria of heterozygosity [19,20,23] and homozygosity [20]. There is also evidence that children heterozygous and homozygous for α⁺-thalassaemia are protected against acidosis [18,20,23] and hyperlactataemia [18]. Comparison of the effects of potential protective factors between studies is complicated because the criteria used to define severe manifestations of malaria often differ between studies. Also, the pathophysiological mechanisms underlying severe malaria may differ between populations. It is unclear how anaemia may be related with these other clinical pathologies but a key role for pro-inflammatory cytokines has been implicated in all clinical sub groups [41]. Hb is an extremely toxic molecule. Outside the erythrocyte and its constituent antioxidant defence systems, the oxidative potential of Hb can cause substantial oxidative tissue damage and release of pro-inflammatory cytokines such as tumour necrosis factor-α [42,43]. Children homozygous for α⁺-thalassaemia release less Hb per erythrocyte during haemolysis and therefore it is plausible that they do not stimulate pro-inflammatory responses as readily as do those of normal genotype. Interestingly, children homozygous for α⁺-thalassaemia have also been shown to be protected against severe nonmalaria disease in this population [18]. Lower Hb concentrations per cell may reduce inflammation during any disease-related haemolysis.

We propose that the microcytosis and higher erythrocyte count associated with α⁺-thalassaemia homozygosity is a selective advantage against SMA. In contrast, the parasite/erythrocyte interaction hypothesis cannot account for protection against SMA as it implies differences in parasite counts by genotype, which we failed to find in any disease state. Whilst our analysis has focused on P. falciparum, this haematological mechanism may protect against other Plasmodium species, such as P. vivax. P. vivax infection can be associated with severe anaemia, and it is interesting to note that the highest frequencies of α⁺-thalassaemia are found in areas where P. vivax is prevalent [1,44]. Since other common disorders of Hb that appear to provide relative protection against severe malaria, notably carriers of beta thalassaemia and homozygous Hb E, also have relatively high microerythrocyte counts [1,45], this haematological mechanism of protection may have broader implications for our understanding of the selection of these host erythrocyte polymorphisms by malaria.

Supporting Information

Figure S1: The Association of Hb Concentration and Erythrocyte Count in Study Children

Hb is positively associated with erythrocyte count, r = 0.94, p < 0.001. Horizontal and vertical lines represent observed median Hb (g/l) and erythrocyte count respectively for each definition of malaria. Solid green line represents acute malaria, dashed green line all hospital malaria. Median (interquartile range) Hb and erythrocyte counts are as follows: severe malaria, 47 g/l (38–79), 2.12 × 10¹²/l (1.58–3.52); all hospital malaria, 61 g/l (44–91), 2.76 × 10¹²/l (1.89–4.09); acute malaria, 72 g/l [47–97], 3.27 × 10¹²/l [2.11–4.44]; mild malaria, 90 g/l [67–103], 4.03 × 10¹²/l [3.12–4.84]; community children, 100 g/l [88–109], 4.78 × 10¹²/l [4.24–5.24].

(158 KB JPG)

Click here for additional data file.^{(159K, jpg)}

Acknowledgments

Our sincere thanks to the children and their parents from Madang, Papua New Guinea, for their participation in this study, Willie Depsone for invaluable help with field work, and to Marta Mellombo for laboratory assistance.

Abbreviations


Hb	haemoglobin

MCH	mean cell haemoglobin

MCV	mean cell volume

PNG	Papua New Guinea

SMA	severe malarial anaemia

Footnotes

¤a Current address: School of Medicine, Swansea University, Swansea, United Kingdom

¤b Current address: Centre for International Health, Curtin University of Technology, Perth, Australia

Author contributions. FJIF performed data analysis. SJA and AA undertook fieldwork. MPA, DJW, and KPD initiated and obtained funding for the project. FJIF, SJA, AA, MPA, DJW, and KPD discussed the results and produced the final manuscript.

Funding: This work was supported by the Wellcome Trust (grant number 035893), The European Community (E.C.) (E.C. grant number IC18-CT98–0359), and the Medical Research Council. KPD and FJIF were supported by a Programme Grant from The Wellcome Trust (grant number 041354). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

References

Weatherall DJ, Clegg JB. The Thalassaemia syndromes. Oxford: Blackwell Science; 2001.
Ganczakowski M, Bowden DK, Maitland K, Williams TN, O'Shaughnessy D, et al. Thalassaemia in Vanuatu, south-west Pacific: frequency and haematological phenotypes of young children. Br J Haematol. 1995;89:485–495. [PubMed]
Williams TN, Maitland K, Ganczakowski M, Peto TE, Clegg JB, et al. Red blood cell phenotypes in the alpha⁺ thalassaemias from early childhood to maturity. Br J Haematol. 1996;95:266–272. [PubMed]
Haldane JBS. The rate of mutation of human genes. Proceedings of the 8th International Congress of Genetics. 1948;35:267–273. In:
Flint J, Hill AV, Bowden DK, Oppenheimer SJ, Sill PR, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature. 1986;321:744–750. [PubMed]
Nagel RL, Roth EF., Jr. Malaria and red cell genetic defects. Blood. 1989;74:1213–1221. [PubMed]
Geary TG, Delaney EJ, Klotz IM, Jensen JB. Inhibition of the growth of Plasmodium falciparum in vitro by covalent modification of hemoglobin. Mol Biochem Parasitol. 1983;9:59–72. [PubMed]
Yuthavong Y, Butthep P, Bunyaratvej A, Fucharoen S, Khusmith S. Impaired parasite growth and increased susceptibility to phagocytosis of Plasmodium falciparum infected alpha-thalassemia or hemoglobin Constant Spring red blood cells. Am J Clin Pathol. 1988;89:521–525. [PubMed]
Senok AC, Li K, Nelson EA, Yu LM, Tian LP, et al. Invasion and growth of Plasmodium falciparum is inhibited in fractionated thalassaemic erythrocytes. Trans R Soc Trop Med Hyg. 1997;91:138–143. [PubMed]
Pattanapanyasat K, Yongvanitchit K, Tongtawe P, Tachavanich K, Wanachiwanawin W, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood. 1999;93:3116–3119. [PubMed]
Luzzi GA, Torii M, Aikawa M, Pasvol G. Unrestricted growth of Plasmodium falciparum in microcytic erythrocytes in iron deficiency and thalassaemia. Br J Haematol. 1990;74:519–524. [PubMed]
Friedman MJ. Oxidant damage mediates variant red cell resistance to malaria. Nature. 1979;280:245–247. [PubMed]
Senok AC, Li K, Nelson EA, Arumanayagam M, Li CK. Flow cytometric assessment of oxidant stress in age-fractionated thalassaemic trait erythrocytes and its relationship to in vitro growth of Plasmodium falciparum. Parasitology. 1998;116(Pt 1):1–6. [PubMed]
Destro-Bisol G, D'Aloja E, Spedini G, Scatena R, Giardina B, et al. Brief communication: resistance to falciparum malaria in alpha-thalassemia, oxidative stress, and hemoglobin oxidation. Am J Phys Anthropol. 1999;109:269–273. [PubMed]
Senok AC, Nelson EA, Li K, Ismaeel AR, Olliaro P, et al. Ultrastructural assessment of Plasmodium falciparum in age-fractionated thalassaemic erythrocytes. Parasitol Res. 2006;98:381–384. [PubMed]
Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G. Protection by alpha-thalassaemia against Plasmodium falciparum malaria: modified surface antigen expression rather than impaired growth or cytoadherence. Immunol Lett. 1991;30:233–240. [PubMed]
Ifediba TC, Stern A, Ibrahim A, Rieder RF. Plasmodium falciparum in vitro: diminished growth in hemoglobin H disease erythrocytes. Blood. 1985;65:452–455. [PubMed]
Allen SJ, O'Donnell A, Alexander ND, Alpers MP, Peto TE, et al. alpha⁺-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A. 1997;94:14736–14741. [PubMed]
Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, et al. The effect of alpha(⁺)-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med. 2006. e158 doi: 10.1371/journal.pmed.0030158.
Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK, et al. Both heterozygous and homozygous alpha+ thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood. 2005;106:368–371. [PubMed]
Imrie H, Fowkes FJ, Michon P, Tavul L, Hume JC, et al. Haptoglobin levels are associated with haptoglobin genotype and {alpha}⁺-thalassemia in a malaria-endemic area. Am J Trop Med Hyg. 2006;74:965–971. [PubMed]
Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah RN, Dietz E, et al. {alpha}⁺-thalassemia protects African children from severe malaria. Blood. 2004;104:2003–2006. [PubMed]
May J, Evans JA, Timmann C, Ehmen C, Busch W, et al. Hemoglobin variants and disease manifestations in severe falciparum malaria. JAMA. 2007;297:2220–2226. [PubMed]
Williams TN, Mwangi TW, Wambua S, Peto TE, Weatherall DJ, et al. Negative epistasis between the malaria-protective effects of alpha(+)-thalassemia and the sickle cell trait. Nat Genet. 2005;37:1253–1257. [PubMed]
Wambua S, Mwacharo J, Uyoga S, Macharia A, Williams TN. Co-inheritance of alpha+-thalassaemia and sickle trait results in specific effects on haematological parameters. Br J Haematol. 2006;133:206–209. [PubMed]
[No author listed] Trans R Soc Trop Med Hyg. Suppl 2. Vol. 84. World Health Organization, Division of Control of Tropical Diseases; 1990. Severe and complicated malaria; pp. 1–65.
Allen SJ, O'Donnell A, Alexander ND, Clegg JB. Severe malaria in children in Papua New Guinea. QJM. 1996;89:779–788. [PubMed]
Bruce MC, Donnelly CA, Alpers MP, Galinski MR, Barnwell JW, et al. Cross-species interactions between malaria parasites in humans. Science. 2000;287:845–848. [PubMed]
Stohlman F., Jr. Humoral regulation Of erythropoiesis xiv: a model for abnormal erythropoiesis in thalassemia. Ann N Y Acad Sci. 1964;119:578–585. [PubMed]
Menendez C, Fleming AF, Alonso PL. Malaria-related anaemia. Parasitol Today. 2000;16:469–476. [PubMed]
Bunyaratvej A, Fucharoen S, Butthep P, Sae-ung N, Kamchonwongpaisan S, et al. Alterations and pathology of thalassemic red cells: comparison between alpha- and beta-thalassemia. Southeast Asian J Trop Med Public Health. 1995;26(Suppl 1):257–260. [PubMed]
Chinprasertsuk S, Wanachiwanawin W, Pattanapanyasat K, Tatsumi N, Piankijagum A. Relation of haemolytic anaemia and erythrocyte-bound IgG in alpha- and beta-thalassaemic syndromes. Eur J Haematol. 1997;58:86–91. [PubMed]
Rachmilewitz EA, Treves A, Treves AJ. Susceptibility of thalassemic red blood cells to phagocytosis by human macrophages in vitro. Ann N Y Acad Sci. 1980;344:314–322. [PubMed]
Rees DC, Williams TN, Maitland K, Clegg JB, Weatherall DJ. Alpha thalassaemia is associated with increased soluble transferrin receptor levels. Br J Haematol. 1998;103:365–369. [PubMed]
Cockburn IA, Mackinnon MJ, O'Donnell A, Allen SJ, Moulds JM, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A. 2004;101:272–277. [PubMed]
David PH, Handunnetti SM, Leech JH, Gamage P, Mendis KN. Rosetting: a new cytoadherence property of malaria-infected erythrocytes. Am J Trop Med Hyg. 1988;38:289–297. [PubMed]
Petz L, Garraty G. Acquired Immune Hemolytic Anemias. New York, NY: Churchill Livingstone; 1980.
Rowe A, Obeiro J, Newbold CI, Marsh K. Plasmodium falciparum rosetting is associated with malaria severity in Kenya. Infect Immun. 1995;63:2323–2326. [PMC free article] [PubMed]
Carlson J, Nash GB, Gabutti V, al-Yaman F, Wahlgren M. Natural protection against severe Plasmodium falciparum malaria due to impaired rosette formation. Blood. 1994;84:3909–3914. [PubMed]
Udomsangpetch R, Sueblinvong T, Pattanapanyasat K, Dharmkrong-at A, Kittikalayawong A, et al. Alteration in cytoadherence and rosetting of Plasmodium falciparum-infected thalassemic red blood cells. Blood. 1993;82:3752–3759. [PubMed]
Mackintosh CL, Beeson JG, Marsh K. Clinical features and pathogenesis of severe malaria. Trends Parasitol. 2004;20:597–603. [PubMed]
McFaul SJ, Bowman PD, Villa VM. Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood. J Lab Clin Med. 2000;135:263–269. [PubMed]
Alayash AI. Hemoglobin-based blood substitutes and the hazards of blood radicals. Free Radic Res. 2000;33:341–348. [PubMed]
Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol. 2006;22:353–358. [PubMed]
Fairbanks VF, Gilchrist GS, Brimhall B, Jereb JA, Goldston EC. Hemoglobin E trait reexamined: a cause of microcytosis and erythrocytosis. Blood. 1979;53:109–115. [PubMed]

Articles from PLoS Medicine are provided here courtesy of
Public Library of Science